search
Back to results

An Educational Intervention for Patients With Bladder Cancer

Primary Purpose

Bladder Cancer

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Education Intervention
Nutrition Intervention
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bladder Cancer focused on measuring Bladder Cancer, Intervention, Education, Randomized Controlled Trials

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Phase 1 (Focus groups/ In-depth Interview)

Inclusion Criteria:

  • treatment of invasive Bladder Cancer a with cystectomy and one of the three major urinary diversion methods
  • English speaking
  • between the ages of 18 and 85
  • able and willing to provide informed consent
  • may have received neoadjuvant or adjuvant chemotherapy, radiation therapy, and immunotherapy (BCG)

Exclusion Criteria:

  • metastatic disease or cancer recurrence
  • presence of other primary cancers
  • no access to a telephone

Phase 2 (randomized-controlled-study)

Additional Exclusion Criteria:

- treatment decision is made and /beginning/completion of treatment.

Sites / Locations

  • Icahn School of Medicine at Mount Sinai
  • James J. Peters VA Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Education Intervention

Nutrition Intervention

Arm Description

In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.

In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery

Outcomes

Primary Outcome Measures

Decisional Regret Scale
The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
The intervention is designed to enhance treatment decision making.
Decisional Self-Efficacy Scale
The intervention is designed to enhance treatment decision making.
Decisional Self-Efficacy Scale
The intervention is designed to enhance treatment decision making.
Decisional Self-Efficacy Scale
The intervention is designed to enhance treatment decision making.
Decisional Self-Efficacy Scale
The intervention is designed to enhance treatment decision making.
Treatment-related Values
The intervention is designed to enhance treatment decision making.
Treatment-related Values
The intervention is designed to enhance treatment decision making.
Treatment-related Values
The intervention is designed to enhance treatment decision making.
Treatment-related Values
The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Decisional Regret Scale
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.

Secondary Outcome Measures

quality of life
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
quality of life
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
quality of life
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
quality of life
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
post-surgical self-care
FACT-BL Ca additional concern
post-surgical self-care
FACT-BL Ca additional concern
post-surgical self-care
FACT-BL Ca additional concern
post-surgical self-care
FACT-BL Ca additional concern
CES-D scale Illness Perception Questionnaire (IPQ)
CES-D scale Illness Perception Questionnaire (IPQ)
CES-D scale Illness Perception Questionnaire (IPQ)
CES-D scale Illness Perception Questionnaire (IPQ)
Cancer worries scale
Cancer worries scale
Cancer worries scale
Cancer worries scale

Full Information

First Posted
July 30, 2013
Last Updated
August 3, 2017
Sponsor
Icahn School of Medicine at Mount Sinai
search

1. Study Identification

Unique Protocol Identification Number
NCT01915121
Brief Title
An Educational Intervention for Patients With Bladder Cancer
Official Title
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
June 30, 2017 (Actual)
Study Completion Date
June 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Icahn School of Medicine at Mount Sinai

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer. Bladder cancer (BL Ca) is the 5th most commonly diagnosed cancer in the US . BL Ca is more common among men than women and 90% of all patients are over the age of 55. Surgery to remove the bladder followed by one of three diversion techniques (i.e., ileal conduit, continent reservoir, and neobladder) is the standard therapy following invasive bladder cancer. The emotional, functional, physical, and social impact of invasive Bl Ca treatment on patients' QOL and adjustment can be devastating. This impact significantly varies by treatment option. Treatment decision making in for BL Ca is difficult at best and potentially susceptible to a number of cognitive and affective factors (e.g., patients' emotional reaction, values, and expectations). Thus, in addition to adjusting to a potential life-threatening disease, having to cope with uncertainty about the efficacy and outcomes of different treatment options adds to the overall distress and may impair effective decision-making. In spite of increasing efforts in health communication and patient education, no study has examined treatment decision making among invasive bladder patients or has provided an educational intervention to facilitate treatment decision making among this population. To this end, and guided by the Self-Regulation theory (SRT) that emphasizes the role of cognitive and emotional factors in decision making, we have designed and pilot tested the acceptability of a preliminary educational and training experiential intervention (ETE) to address this gap in the literature. The ETE intervention uses new and innovative educational strategies and methods to educate patients about their treatment options and to facilitate their treatment decision making.
Detailed Description
The goals of the study are: 1) to further enhance the design and application of the ETE intervention, and 2) to provide data on the efficacy of the refined ETE intervention in a randomized-controlled study (RCT). To achieve these 2 goals, the study is divided in to 2 phases. PHASE 1: To enhance and refine the design and application of the preliminary ETE intervention: Aim 1-a: To explore knowledge, beliefs, values and expectations about treatment options, treatment decision making, and quality of life (QOL) among patients with BL Ca. To achieve Aim 1-a of Phase 1, as a first step, 2 focus groups (FG; N = 10 each) of invasive BL Ca patients will be conducted to a) examine knowledge, beliefs, values, expectations, and affective responses about treatment options and treatment decision making, b) record difficulties and problems in post-surgical health care (e.g., using stoma appliances and catheters), and c) explore concerns patients have as they live with the impact of treatment. The ETE intervention will be refined based on FG results. Aim 1-b: To explore patients' acceptability of the refined ETE intervention. To achieve Aim 1-b of Phase 1, additional 2 FG (FG; N = 10 each) of BL Ca survivors will be conducted to solicit input about the design and acceptability of the refined ETE intervention. PHASE 2: Aim 2. To assess the efficacy of the ETE intervention in small RCT To achieve Aim 2 of Phase 2, a two-group RCT (standard care (SC) plus time and attention control condition, N = 62 patients; SC plus ETE intervention N = 62 patients) will be conducted to examine the efficacy of the ETE intervention. Phase 2 will provide a) a test of the efficacy of the refined ETE intervention for reducing decisional conflict and regret, and improving QOL and post-treatment stoma and pouch care controlling for potential clinical and socio-demographic covariates (e.g., treatment type, age).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer
Keywords
Bladder Cancer, Intervention, Education, Randomized Controlled Trials

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Education Intervention
Arm Type
Active Comparator
Arm Description
In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
Arm Title
Nutrition Intervention
Arm Type
Placebo Comparator
Arm Description
In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
Intervention Type
Behavioral
Intervention Name(s)
Education Intervention
Intervention Description
1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
Intervention Type
Behavioral
Intervention Name(s)
Nutrition Intervention
Intervention Description
1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
Primary Outcome Measure Information:
Title
Decisional Regret Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
Baseline
Title
Decisional Regret Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
1 month follow up
Title
Decisional Regret Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
3 month follow up
Title
Decisional Regret Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
6 month follow up
Title
Decisional Self-Efficacy Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
Baseline
Title
Decisional Self-Efficacy Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
1 month follow up
Title
Decisional Self-Efficacy Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
3 month follow up
Title
Decisional Self-Efficacy Scale
Description
The intervention is designed to enhance treatment decision making.
Time Frame
6 month follow up
Title
Treatment-related Values
Description
The intervention is designed to enhance treatment decision making.
Time Frame
Baseline
Title
Treatment-related Values
Description
The intervention is designed to enhance treatment decision making.
Time Frame
1 month follow up
Title
Treatment-related Values
Description
The intervention is designed to enhance treatment decision making.
Time Frame
3 month follow up
Title
Treatment-related Values
Description
The intervention is designed to enhance treatment decision making.
Time Frame
6 month follow up
Title
Decisional Regret Scale
Description
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Time Frame
Baseline
Title
Decisional Regret Scale
Description
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Time Frame
1 month follow up
Title
Decisional Regret Scale
Description
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Time Frame
3 month follow up
Title
Decisional Regret Scale
Description
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making.
Time Frame
6 month follow up
Secondary Outcome Measure Information:
Title
quality of life
Description
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
Time Frame
Baseline
Title
quality of life
Description
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
Time Frame
1 month follow up
Title
quality of life
Description
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
Time Frame
3 month follow up
Title
quality of life
Description
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
Time Frame
6 month follow up
Title
post-surgical self-care
Description
FACT-BL Ca additional concern
Time Frame
Baseline
Title
post-surgical self-care
Description
FACT-BL Ca additional concern
Time Frame
1 month follow up
Title
post-surgical self-care
Description
FACT-BL Ca additional concern
Time Frame
3 month follow up
Title
post-surgical self-care
Description
FACT-BL Ca additional concern
Time Frame
6 month follow up
Title
CES-D scale Illness Perception Questionnaire (IPQ)
Time Frame
Baseline
Title
CES-D scale Illness Perception Questionnaire (IPQ)
Time Frame
1 month follow up
Title
CES-D scale Illness Perception Questionnaire (IPQ)
Time Frame
3 month follow up
Title
CES-D scale Illness Perception Questionnaire (IPQ)
Time Frame
6 month follow up
Title
Cancer worries scale
Time Frame
Baseline
Title
Cancer worries scale
Time Frame
1 month follow up
Title
Cancer worries scale
Time Frame
3 month follow up
Title
Cancer worries scale
Time Frame
6 month follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Phase 1 (Focus groups/ In-depth Interview) Inclusion Criteria: treatment of invasive Bladder Cancer a with cystectomy and one of the three major urinary diversion methods English speaking between the ages of 18 and 85 able and willing to provide informed consent may have received neoadjuvant or adjuvant chemotherapy, radiation therapy, and immunotherapy (BCG) Exclusion Criteria: metastatic disease or cancer recurrence presence of other primary cancers no access to a telephone Phase 2 (randomized-controlled-study) Additional Exclusion Criteria: - treatment decision is made and /beginning/completion of treatment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nihal E Mohamed, PhD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
James J. Peters VA Medical Center
City
The Bronx
State/Province
New York
ZIP/Postal Code
10468
Country
United States

12. IPD Sharing Statement

Learn more about this trial

An Educational Intervention for Patients With Bladder Cancer

We'll reach out to this number within 24 hrs